#Japan #Tokyo #Series B Funding #CaTe Inc. #Heart Rehab

CaTe Inc. Achieves Milestone in Series B Funding

CaTe Inc., headquartered in Bunkyo-ku, Tokyo, led by CEO Kazuhira Terashima, has recently secured additional funding of 1.73 billion yen in what is dubbed the Series B Round Final Close. This funding was raised through a third-party allotment of shares, with significant participation from Mitsui Sumitomo Trust Bank and Gokin Capital LLC, among others. This achievement brings the company’s total raised capital to 2.35 billion yen since its founding, enabling it to further invest in research and development, which now totals 2.54 billion yen including 190 million yen earmarked for research.

This recent funding will allow CaTe to accelerate its development of innovative heart rehabilitation programs and medical devices. The need for such solutions is urgent, as cardiovascular diseases remain the second leading cause of death in Japan, necessitating effective management solutions to improve patient outcomes.

Insight from Investors

Leading the charge in this investment is Kazuya Yoneda, head of Impact Equity Investments at Mitsui Sumitomo Trust Bank. Yoneda emphasizes the critical importance of addressing the challenges associated with traditional cardiac rehabilitation. He points out that while the benefits of such rehabilitation are well-documented, the participation rates have been alarmingly low due to hurdles related to time and accessibility for patients. CaTe is poised to tackle these obstacles effectively by developing a remote cardiac rehabilitation system that is not only safe and efficient but also user-friendly for both patients and healthcare providers. This initiative aligns perfectly with the bank's vision of enhancing well-being across generations and supporting impactful investments.

Shuichi Ida, president of Gokin Capital, shares similar enthusiasm for CaTe's approach. He expresses optimism that the development of at-home cardiac rehabilitation devices will be groundbreaking in resolving significant societal healthcare issues. He anticipates that patients and their families will gain peace of mind in managing their rehabilitation, facilitating a stable lifestyle.

Vision of Growth from CaTe

The CEO of CaTe, Kazuhira Terashima, along with CFO Tomoki Miyazaki, voiced their appreciation for the support from their investors. They view this funding as a critical step in taking the company's business to the next level. Terashima asserts that they acknowledge the high expectations from their stakeholders and are committed to delivering better treatment options for patients. He reinforces CaTe's mission of creating a healthy and vibrant society rooted in the philosophy that “Exercise is Medicine.” The company is dedicated to sustainable growth and bringing innovative health solutions to market.

Company Profile

Founded on March 18, 2020, CaTe Inc. is striving to transform healthcare with innovative medical technology. The company addresses monumental challenges within the medical field, primarily focusing on cardiac rehabilitation. With its headquarters located at the Sky Vision Building in Tokyo, and a branch office in Nagoya, CaTe operates under the second-class medical device sales license (13B2X10514).

For additional information, you can explore their official website: CaTe Inc..